WeightControl.com Interview with:
Kathrine Kold Sørensen, postdoc, PhD, cand.scient.san.publ
Copenhagen University Hospital – Steno Diabetes Center Copenhagen
Department for Clinical and Translational Research
Denmark

WeightControl.com: What is the background for this study?
Response: GLP-1 receptor agonists are widely used in the treatment of type 2 diabetes and obesity and are known to improve weight and metabolic outcomes. Beyond weight loss, however, the mechanisms underlying these benefits are not fully understood. Smaller studies and case reports have suggested that GLP-1 RAs may influence food preferences.